LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRXBiotechnology
Healthcare
$40.06 -1.30%
-$0.39 today
- Market cap
- $1.30B
- Beta
- 0.71
- P/E (TTM)
- -21.4
- EPS (TTM)
- -$1.39
52W Low $13.36High $33.47
Volume 0.36M
Average 0.23M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$30.40M
FY 2025 · Annual
Net Income
-$25.20M
FY 2025 · Annual
Income Statement
USD
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — |
| Research & Development | 1.35M | 7.85M | 51.17M | 16.74M |
| Selling, General & Admin | 1.46M | 3.53M | 13.66M | 13.66M |
| Operating Expenses | 2.81M | 11.38M | 64.83M | 30.4M |
| Depreciation & Amortization | 2K | 4K | 91K | 321K |
| EBITDA | (12.19M) | (1.45M) | (63.01M) | (24.88M) |
| EBITDA Margin | — | — | — | — |
| Operating Income | (2.81M) | (11.38M) | (64.83M) | (30.4M) |
| Operating Margin | — | — | — | — |
| Interest Income | 73K | 811K | 1.72M | 3.92M |
| Interest Expense | 2.15M | 4.83M | 0 | 0 |
| Other Income / Expenses | (11.54M) | 5.1M | 1.73M | 5.2M |
| Income Before Tax | (14.35M) | (6.27M) | (63.1M) | (25.2M) |
| Pre-Tax Margin | — | — | — | — |
| Income Tax Expense | 1K | 1K | 1K | 1K |
| Net Income | (14.35M) | (6.28M) | (63.1M) | (25.21M) |
| Net Margin | — | — | — | — |
| EPS (Basic) | (4.05) | (1.77) | (17.83) | (1.00) |
| EPS (Diluted) | (4.05) | (1.77) | (17.83) | (1.00) |
| 3.54M | 3.54M | 3.54M | 25.3M | |
| 3.54M | 3.54M | 3.54M | 25.3M |
LBRX Earnings Waterfall · TTM
NASDAQ:LBRX · Revenue to Net Income
Key Ratios
EPS$-21.47
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-12.4
P/S Ratio0.0
Analysis
$0 of revenue converted into -$39.2M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-21.47, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | |
| 8-K | Current report | Nov 5, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 13, 2026 | |
| SC 13G/A | SC 13G/A filing | Oct 13, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 13, 2026 |
How much revenue does LBRX generate?
LB Pharmaceuticals Inc Common Stock (LBRX) reported $0.00 of revenue in fiscal 2025.
Is LBRX profitable?
LB Pharmaceuticals Inc Common Stock (LBRX) reported -$25.20M of net income.
Continue the stock analysis
Jump to another research area for this company.